AorTech International PLC Result of General Meeting and Total Voting Rights (2039I)
31 March 2020 - 8:28PM
UK Regulatory
TIDMAOR
RNS Number : 2039I
AorTech International PLC
31 March 2020
31 March 2020
AorTech International plc
("AorTech" or the "Company")
Result of General Meeting
And
Total Voting Rights
AorTech International plc (AIM: AOR), the licensor of the
world's long-term implantable biostable polymer (Elast-Eon(TM) )
and developer of medical devices utilising the key properties of
Elast-Eon(TM) , announces that all resolutions put to Shareholders
at the General Meeting held earlier today were duly passed.
Application has therefore been made for 1,500,000 new Ordinary
Shares to be admitted to trading on AIM. Admission is expected to
occur at 8.00 am on 1 April 2020.
Following Admission, the Company will have 16,186,608 Ordinary
Shares in issue and admitted to trading on AIM. This figure may be
used by Shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the Financial Conduct Authority's Disclosure Guidance and
Transparency Rules.
As previously announced, following Completion, the Company
intends to change its name to RUA Life Sciences plc. However, as
announced on 25 March 2020, implementation will be delayed until
the Company is satisfied that a normal service is available from
Companies House. A further announcement will be made in due
course.
Immediately following Completion, David Richmond will become
Group Chief Executive Officer of AorTech.
This announcement should be read in conjunction with the full
text of the Circular which was posted to Shareholders on 11 March
2020, copies of which are available on the Company's website at
www.aortech.net. Capitalised terms in this announcement have the
same meaning as given in the Circular.
This announcement contains inside information and is disclosed
in accordance with the Company's obligations under the Market Abuse
Regulation (EU) No 596/2014.
For further information contact:
AorTech International plc Tel: +44 (0)7730 718296
Bill Brown, Chairman
Shore Capital Tel: +44 (0)20 7408 4080
Tom Griffiths/David Coaten
About AorTech
AorTech has developed biostable, implantable polymers, including
Elast-Eon(TM) and ECSil(TM), now manufactured on its behalf by
Biomerics LLC in Utah, USA. Elast-Eon(TM) and ECSil(TM)'s
biostability is comparable to silicone while exhibiting excellent
mechanical, blood contacting and flex-fatigue properties. These
polymers can be processed using conventional thermoplastic
extrusion and moulding techniques. With over 6 million implants and
over 10 years of successful clinical use, AorTech polymers are
proven in long term life enabling applications.
In addition to continuing to exploit AorTech's Intellectual
Property related to Elast-Eon(TM), AorTech is now incorporating
this material into a number of medical devices of our own design.
Elast-Eon(TM) has first class long term blood contacting properties
and, as a result, all of the initial products being developed are
for the cardio vascular field. Each device is being designed to
have improved clinical outcomes over current device technology,
eliminating the use of animal sourced material whilst allowing
procedures to remain the same, therefore avoiding having to retrain
surgeons in new ways of operating.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ROMGCGDXLDXDGGB
(END) Dow Jones Newswires
March 31, 2020 05:28 ET (09:28 GMT)
Rua Life Sciences (LSE:RUA)
Historical Stock Chart
From Apr 2024 to May 2024
Rua Life Sciences (LSE:RUA)
Historical Stock Chart
From May 2023 to May 2024